a Immunization Safety Office, Division of Healthcare Quality Promotion , National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA.
b Logistics Health Incorporated , La Crosse, Wisconsin , USA.
Hum Vaccin Immunother. 2019;15(3):669-676. doi: 10.1080/21645515.2018.1549453. Epub 2019 Jan 8.
To evaluate the hypothesis that receipt of anthrax vaccine adsorbed (AVA) increases the risk of atrial fibrillation in the absence of identifiable underlying risk factors or structural heart disease (lone atrial fibrillation).
We conducted a retrospective population-based cohort study among U.S. military personnel who were on active duty during the period from January 1, 1998 through December 31, 2006. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes were used to identify individuals diagnosed with atrial fibrillation in the Defense Medical Surveillance System, and electronic records were screened to include only individuals without evidence of predisposing medical conditions. We used multivariable Poisson regression to estimate the risk of lone atrial fibrillation after exposure to AVA. We also evaluated possible associations with influenza and smallpox vaccines.
Our study population consisted of 2,957,091individuals followed for 11,329,746 person-years of service. Of these, 2,435 met our case definition for lone atrial fibrillation, contributing approximately 8,383 person-years of service. 1,062,176 (36%) individuals received at least one dose of AVA; the median person time observed post-exposure was 3.6 years. We found no elevated risk of diagnosed lone atrial fibrillation associated with AVA (adjusted risk ratio = 0.99; 95% confidence interval = 0.90, 1.09; p = 0.84). No elevated risk was observed for lone atrial fibrillation associated with influenza or smallpox vaccines given during military service.
We did not find an increased risk of lone atrial fibrillation after AVA, influenza or smallpox vaccine. These findings may be helpful in planning future vaccine safety research.
评估在无明确潜在风险因素或结构性心脏病(孤立性心房颤动)的情况下,接种炭疽疫苗吸附剂(AVA)是否会增加心房颤动的风险这一假说。
我们在美国现役军人中开展了一项回顾性基于人群的队列研究,这些军人在 1998 年 1 月 1 日至 2006 年 12 月 31 日期间服役。使用国际疾病分类,第九修订版,临床修正(ICD-9-CM)代码在国防医疗监测系统中确定被诊断为心房颤动的个体,并且筛选电子记录以仅包括无潜在疾病状况证据的个体。我们使用多变量泊松回归来估计暴露于 AVA 后发生孤立性心房颤动的风险。我们还评估了与流感和天花疫苗的可能关联。
我们的研究人群由 2957091 名个体组成,随访 11329746 人年的服役期。其中,2435 名符合我们的孤立性心房颤动病例定义,占约 8383 人年的服务期。1062176 人(36%)至少接受了一剂 AVA;暴露后中位观察时间为 3.6 年。我们发现 AVA 与诊断为孤立性心房颤动的风险增加无关(调整后的风险比= 0.99;95%置信区间= 0.90,1.09;p = 0.84)。在服役期间接种流感或天花疫苗与孤立性心房颤动的风险增加无关。
我们没有发现 AVA、流感或天花疫苗接种后孤立性心房颤动的风险增加。这些发现可能有助于规划未来的疫苗安全研究。